Maravai LifeSciences Holdings Inc. Class A Common Stock vs ZTO Express (Cayman) Inc. American Depositary Shares each representing one Class A ordinary share. — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while ZTO Express (Cayman) Inc. American Depositary Shares each representing one Class A ordinary share. trades at $20.05 (market cap $15.45B). The key difference: ZTO Express (Cayman) Inc. American Depositary Shares each representing one Class A ordinary share. is far larger — about 15.9× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and ZTO Express (Cayman) Inc. American Depositary Shares each representing one Class A ordinary share. pays a 3.34% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| MRVI | ZTO | |
|---|---|---|
Market Cap | $972.90M | $15.45B |
Volume | 4,325,710 | 1,928,522 |
Sector | Health | Industrials |
52-Week High | $9.00 | $25.88 |
52-Week Low | $2.83 | $18.59 |
Typical Hold Time | 0 Days | — |
Enterprise Value | $1.08B | $14.06B |
Dividend Yield | — | 3.34% |
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
ZTO Express trades at $20.67, up 1.08% with a bullish technical signal despite mixed moving averages. The company shows strong fundamentals with $49.1B revenue, 19.03% net margin, and attractive valuation at P/E of 10.79. Recent Q2 2026 earnings beat expectations with 11% EPS growth, while analyst consensus remains strongly positive with 70% buy ratings.
ZTO presents compelling value with 50% upside to consensus target of $30.85, supported by pricing power and cost efficiencies. Risks include competitive pressures in China's delivery market and negative cash flow trends. The stock offers growth potential through market share gains and improved pricing environment.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →ZTO Express provides domestic and international express delivery services in China. Its network-partner model combines ZTO's sorting and trunk transportation with partners' pickup and last-mile delivery.
Read more on ZTO →